Fentanyl
Brand names: Sublimaze, Actiq, Duragesic
Fentanyl is a potent synthetic opioid analgesic used in emergency and critical care for severe acute pain and to facilitate procedures and rapid-sequence induction.
Adult dose
Paediatric dose
Dose adjustments
SPC §4.2, verbatim: 'Renal Impairment: In patients with renal impairment reduced dosing of fentanyl should be considered and these patients should be observed carefully for signs of fentanyl toxicity.' US label §8.5 adds: 'Fentanyl is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function... care should be taken in dose selection, and it may be useful to monitor renal function.'
Not stated — no hepatic-impairment dosing statement appears in any fetched section of the UK SPC or the US label. The only mention is US §8.5, which notes elderly patients more often have 'decreased hepatic, renal, or cardiac function'. Verify before use in hepatic impairment.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
The calculator uses the LOWER end of the SPC's initial range. SPC §4.2 paediatric table, verbatim — 'Children aged 2 to 11 years old: Spontaneous Respiration 2-11 yrs Initial 1-3 micrograms/kg, Supplemental 1-1.25 micrograms/kg; Assisted Ventilation 2-11 yrs Initial 1-3 micrograms/kg, Supplemental 1-1.25 micrograms/kg.' 'Children aged 12 to 17 years old: Follow adult dosage.' Verbatim safety statement: 'Techniques that involve analgesia in a spontaneous breathing child should only be used as part of an anaesthetic technique, or given as part of a sedation/analgesia technique with experienced personnel in an environment that can manage sudden chest wall rigidity requiring intubation, or apnoea requiring airway support.' No figure is given in this SPC for children under 2 years; the US label states 'The safety and efficacy of Fentanyl Citrate Injection in pediatric patients under two years of age has not been established.' The concentration used for the volume calculation is the fetched product strength — Fentanyl 50 microgram/ml Injection, i.e. 50 micrograms per mL. Intranasal dosing is NOT covered by this label. Verify all under-18 dosing against a children's formulary before administration.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, or to other opioids (SPC §4.3)
- Respiratory depression, obstructive airways disease (SPC §4.3)
- Concurrent administration with monoamine oxidase inhibitors, or within 2 weeks of their discontinuation (SPC §4.3)
- US label §4 lists only 'Hypersensitivity to fentanyl (e.g., anaphylaxis)' — the UK SPC list above is the wider one and is the one applied here
Side effects
- Very common (≥1/10), §4.8: muscle rigidity — 'which may also involve the thoracic muscles' (10.4% in pooled trial data); nausea (26.1%); vomiting (18.6%)
- Common (≥1/100 to <1/10): hypotension (8.8%); hypertension (8.8%); bradycardia (6.1%); sedation (5.3%); tachycardia; arrhythmia; venous pain; dyskinesia; dizziness; agitation; laryngospasm; bronchospasm; apnoea; postoperative confusion; airway complication of anaesthesia
- Uncommon (≥1/1,000 to <1/100): euphoric mood; headache; visual disturbance; phlebitis; blood pressure fluctuation; hyperventilation; hiccups; dysphagia; allergic dermatitis; chills; hypothermia; drug withdrawal syndrome
- Not known: respiratory depression; cardiac arrest; convulsions; loss of consciousness; myoclonus; delirium; drug dependence; hypersensitivity including anaphylactic shock, anaphylactic reaction and urticaria; pruritus
- With a concomitant neuroleptic: chills and/or shivering, restlessness, postoperative hallucinatory episodes and extrapyramidal symptoms
- US label §6 (cross-check): 'the most common serious adverse reactions reported to occur with fentanyl are respiratory depression, apnea, rigidity and bradycardia; if these remain untreated, respiratory arrest, circulatory depression or cardiac arrest could occur'
Monitoring
- Airway and ventilation — 'Fentanyl should be given only in an environment where the airway can be controlled and by personnel who can control the airway' (SPC §4.2/§4.4)
- US §2.1, verbatim: 'Ensure that an opioid antagonist, resuscitative and intubation equipment, and oxygen are readily available.'
- US §2.1, verbatim: 'Monitor vital signs routinely. As with other potent opioids, the respiratory depressant effect of fentanyl may persist longer than the measured analgesic effect. The total dose of all opioid agonists administered should be considered by the practitioner before ordering opioid analgesics during recovery from anesthesia.'
- Blood pressure — 'Following intravenous administration of fentanyl, a transient fall in blood pressure may occur, especially in hypovolaemic patients. Appropriate measures to maintain a stable arterial pressure should be taken.' (SPC §4.4)
- Muscle/chest wall rigidity — listed as a very common reaction 'which may also involve the thoracic muscles'; be prepared to manage rigidity requiring intubation
- Renal impairment — 'observed carefully for signs of fentanyl toxicity' (SPC §4.2)
- Signs of misuse, abuse, addiction or tolerance on repeated use, with regular review of the clinical need for analgesic treatment (SPC §4.4)
Clinical monograph
How it works
It is a strong agonist at mu-opioid receptors, producing rapid, short-lasting analgesia and sedation; its high lipophilicity gives fast onset and a short duration after a single dose.
Prescribing in practice
- It is a high-potency opioid that can cause rapid respiratory depression and apnoea, so it must only be used where airway support, oxygen, monitoring and naloxone are immediately available.
- Rapid intravenous administration of higher doses can precipitate chest-wall and glottic rigidity, impairing ventilation.
- Effects are markedly potentiated by other CNS depressants and benzodiazepines, increasing the risk of profound sedation and respiratory compromise.
Monitoring
Monitor respiratory rate, oxygen saturation, sedation level and blood pressure continuously during and after administration.
Counselling the patient
- This is a strong, fast-acting painkiller that can slow your breathing, so you will be closely watched.
- Tell staff at once if you feel very drowsy or short of breath.
- Avoid alcohol and other sedating medicines around the time it is given.
Evidence & guidelines
Fentanyl is an established opioid for acute severe pain and procedural use in emergency and anaesthetic practice.
Reference: NICE; RCEM Pain in Adults Clinical Standards 2022; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Major Haemorrhage Protocol · NICE NG24; UK MHP guidelines
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Featured in these MRCEM clinical pathways
Fentanyl is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.
MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.